The tablet formulation of zanubrutinib (Brukinsa; BeOne) is currently accepted for all 5 indications across numerous hematological cancers.A single cause why the cost tag is so substantial will be to protect the costs of developing and generating the drug. The price compensated via the NHS for this a person-off treatment needs to be set from the pr